The mTORC1 signaling pathway is constitutively activated in almost all acute myelogenous leukemia (AML) patients. We conducted a phase Ib trial combining RAD001 (everolimus), an allosteric inhibitor ...
Activity of the mitochondrial metabolism inhibitor cpi-613 in combination with high dose Ara-C (HDAC) and mitoxantrone in high risk relapsed or refractory acute myeloid leukemia (AML). This is an ASCO ...
MEXICO CITY, Nov. 4, 2025 /PRNewswire/ -- With the firm purpose of strengthening their capabilities in preventing money laundering (AML) and other illicit activities, Mexican banks will implement a ...
Please provide your email address to receive an email when new articles are posted on . Down syndrome remained a significant risk factor for pediatric leukemia, especially acute myeloid leukemia, ...
Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP 1304), an International, Randomized Phase III Trial Led by ANZUP We identified data from eight ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Amphivena Therapeutics highlighted initial data from the dose-escalation portion of the First-in-Human Phase 1 trial evaluating AMV564 in patients with ...
– Encouraging clinical activity with deep responses demonstrated in the KOMET-007 trial with the combination of 600 mg ziftomenib with 7+3 in newly diagnosed patients with NPM1-m and KMT2A-r AML – – ...
Actimab-A significantly potentiated and prolonged efficacy in combination with standard of care targeted therapies including hypomethylating agent azacitidine, FLT3 and menin inhibitors in in-vivo AML ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results